,

Double-blind, multicenter clinical trial to assess the efficacy, tolerance, pharmacokinetics, and anti-transmission effect of Artemether-Lumefantrine + Atovaquone-Proguanil triple therapy versus Artemether-Lumefantrine dual therapy for the treatment of uncomplicated Plasmodium malaria faciparum in children aged 6 months to 5 years.

Northern Partnership

MIVEGEC

Southern Partnership

  • KNUST
  • BNI™
  • USTTB
  • CERMEL
  • IRCB
  • INSTech

Funding

EDCTP (European and Developing Countries Clinical Trials Partnership)

EDCTP

Calendar

2019-2023

Direction

Jerome CLAIN

Jerome Clain

MEDS manager MEDS Manager, University Lecturer
jerome.clai@parisdescartes.fr
Faculty of Pharmacy, Paris

UMR Merit teams

Brigitte

Brigitte TECHER

GECO Manager Head of UMR administration, Head of GECO, Research engineer
brigitte.techer@ird.fr
Paris, Faculty of Pharmacy
Gilles COTTRELL

Gilles COTTRELL

HOPE Manager, Host-Pathogen Interactions Head of HOPE, Research Officer
gilles.cottrell@ird.fr
Faculty of Pharmacy, Paris
Justine Bailly

Justine Bailly

HOPE Manager, Host-Pathogen Interactions Study engineer
justine.bailly@ird.fr
Paris, Faculty of Pharmacy
Sayeh-GUEMOURI

Sayeh GUEMOURI

HOPE Manager, Host-Pathogen Interactions Research engineer, Lab manager
sayeh.guemouri@ird.fr
Paris, Faculty of Pharmacy